Krezsita 100 Tablet contains Sitagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Sitagliptin enhances the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells in a glucose-dependent manner while simultaneously decreasing glucagon secretion from pancreatic alpha cells. This dual action helps improve glycemic control without causing significant hypoglycemia. Krezsita 100 is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The tablet is administered orally once daily, with or without food, and dosage adjustments may be necessary in patients with renal impairment. Common adverse effects include nasopharyngitis, headache, and upper respiratory tract infections, with a low risk of hypoglycemia when used as monotherapy. Krezsita 100 should be used cautiously in patients with a history of pancreatitis and is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose levels and renal function is recommended during therapy.